NDC 0143-9355-01 - Vancomycin Hydrochloride
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0143-9355
- Requested NDC
- 0143-9355-01
- Package NDCs from labels
- 0143-9355-01, 0143-9355-10
- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Effective date
- 2022-02-25
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Vancomycin Hydrochloride for Injection, USP | Hikma Pharmaceuticals USA Inc. | 2022-02-25 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0143-9355-01 | Vancomycin Hydrochloride | 1 in 1 VIAL | INJECTION, POWDER, LYOPHILIZED, | 1 | 4 | |
| 0143-9355-10 | Vancomycin Hydrochloride | 10 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 10 | 4 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0143-9355-01 | EA - Each | 0143-9355 | 5d2ce172-3a6c-46b5-a04f-0179751bc0ea | 1 | 2019-05-02 |
| 0143-9355-10 | EA - Each | 0143-9355 | 8354e7fd-4deb-4915-8894-9ab70c2381ee | 1 | 2019-05-02 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| TYZAVAN | VANCOMYCIN | Hikma Pharmaceuticals USA Inc. | 72e9c5e2-07cc-4a8b-ba64-b2e7619ea560 | 2026-08-19 | Warnings, Adverse reactions | 6Q205EH1VU |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Avenacy, LLC | c757e65b-ca6f-4c00-afe2-025962b43d31 | 2026-07-31 | Warnings, Adverse reactions | 1807518 |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Hospira, Inc. | f2901045-904f-47bd-74a1-c561facd7f25 | 2026-04-01 | Warnings, Adverse reactions | 1807518 |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | GLENMARK PHARMACEUTICALS INC., USA | 0543b2b5-b1c7-4ad6-b38c-3be0086f0e06 | 2025-12-23 | Warnings, Adverse reactions | 1807518 |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | STERISCIENCE SPECIALTIES PRIVATE LIMITED | 2c355037-6a1e-4846-872a-471ccbdc8d54 | 2025-10-31 | Warnings, Adverse reactions | 1807518 |
| VANCOMYCIN HYDROCHLORIDE | VANCOMYCIN HYDROCHLORIDE | HIKMA PHARMACEUTICALS USA INC. | 8eccafe8-40c9-495a-872d-7f45a98ee759 | 2025-08-13 | Warnings, Adverse reactions | 1807518 |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Sagent Pharmaceuticals | f623889c-a47a-4b3a-b3a9-e04051f5c2df | 2025-05-28 | Warnings, Adverse reactions | 1807518 |
| VANCOMYCIN HYDROCHLORIDE | VANCOMYCIN HYDROCHLORIDE | Fresenius Kabi USA, LLC | f604d399-fded-4f4f-8efe-af558ed07b9d | 2025-05-15 | Warnings, Adverse reactions | 1807518 |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Gland Pharma Limited | 65e5f2ee-934c-40d7-967c-00d085f84ffd | 2025-04-24 | Warnings, Adverse reactions | 1807518 |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Fresenius Kabi USA, LLC | 9bfe30f8-c662-4af3-bc82-f0102eef8952 | 2025-03-17 | Warnings, Adverse reactions | 1807518 |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Mylan Institutional LLC | caf22ccb-df75-45ea-a1d0-ccb2d37272fb | 2024-06-07 | Warnings, Adverse reactions | 1807518 |
| Vancomycin hydrochloride | VANCOMYCIN HYDROCHLORIDE | Meitheal Pharmaceuticals Inc. | e5e26614-4119-40cc-b092-48ab97a41287 | 2023-03-27 | Warnings, Adverse reactions | 1807518 |
| Vancomycin | VANCOMYCIN | Xellia Pharmaceuticals USA LLC | 60bee69b-be70-412c-9e83-a24a0a8a5e7b | 2023-03-23 | Boxed warning, Warnings, Adverse reactions | 6Q205EH1VU |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Hikma Pharmaceuticals USA Inc. | 86950e7c-0114-47e9-8891-e09e595c48c3 | 2022-02-25 | Warnings, Adverse reactions | ANDA206616 0143-9355-01 0143-9355-10 0143-9355 00143935501 1807518 e298d434-6e7e-4a46-9744-a098386a89d6 86950e7c-0114-47e9-8891-e09e595c48c3 6Q205EH1VU |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.